Skip to main content
SpringerLink
Log in

Age-Related Changes in Protein Binding of Drugs

Implications for Therapy

  • Special Populations
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

The plasma protein binding of drugs, particularly those that are highly bound, may have significant clinical implications. Although protein binding is a major determinant of drug action, it is only one of a myriad of factors that influence drug disposition. The extent of protein binding is a function of drug and protein concentrations, the affinity constant for the drug-protein interaction and the number of protein binding sites per class of binding site.

Age-related changes in protein binding are usually not clinically important in drug therapy. Albumin levels are generally decreased in the elderly, whereas α1-acid glycoprotein levels are not altered by age per se. Alterations in plasma protein binding that occur in the elderly are generally not attributed to age, but rather to physiological and pathophysiological changes or disease states that may occur more frequently in the elderly and most often account for altered protein binding. Age-related physiological changes, such as decreased renal function, decreased hepatic function and decreased cardiac output, generally produce more clinically significant alterations in drug disposition than that seen with alterations in drug plasma protein binding.

An understanding of the inter-relationships between drug concentrations, protein binding, the physiology of aging, disease, pharmacokinetics and pharmacodynamics is necessary for effective therapeutic monitoring. Monitoring of unbound drug concentrations simplifies these relationships and provides the fundamental information needed for dosage regimen development and adjustment. Drug therapy in the elderly should be individualised taking into account all of these factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Table I

Similar content being viewed by others

References

  1. Greenblatt DJ, Sellers EM, Koch-Weser J. Importance of protein binding for the interpretation of serum of plasma drug concentrations. J Clin Pharmacol 1982 May-Jun; 22(5–6): 259–63.

    PubMed  CAS  Google Scholar 

  2. Ariëns EJ. Drug levels in the target tissue and effect. Clin Pharmacol Ther 1974 Jul; 16(1): 155–75.

    PubMed  Google Scholar 

  3. Oosterhuis B, van Boxtel CJ. Kinetics of drug effects in man. Ther Drug Monit 1988; 10(2): 121–32.

    Article  PubMed  CAS  Google Scholar 

  4. Wright JD, Boudinot FD, Ujhelyi MR. Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet 1996 Jun; 30(6): 445–62.

    Article  PubMed  CAS  Google Scholar 

  5. Blum MR, Riegelman S, Becker CE. Altered protein binding of diphenylhydantoin in uremic plasma [letter]. N Engl J Med 1972 Jan; 286(2): 109.

    PubMed  CAS  Google Scholar 

  6. Odar-Cederlof I, Lunde P, Sjogvist F. Abnormal pharmacokinetics of phenytoin in a patient with uremia. Lancet 1970 Oct; II(7677): 831–2.

    Article  Google Scholar 

  7. Gibaldi M, Koup JR. Pharmacokinetic concepts — drug binding, apparent volume of distribution and clearance. Eur J Clin Pharmacol 1981; 20(4): 299–305.

    Article  PubMed  CAS  Google Scholar 

  8. Kunin CM, Craig WA, Kornguth M, et al. Influence of protein binding on the pharmacologic activity of antibiotics. Ann N Y Acad Sci 1973 Nov; 226: 214–24.

    Article  PubMed  CAS  Google Scholar 

  9. Piafsky KM. Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet 1980 May-Jun; 5(3): 246–62.

    Article  PubMed  CAS  Google Scholar 

  10. Kishino S, Nomura A, Di ZS, et al. Changes in the binding capacity of alpha-1-acid glycoprotein in patients with renal insufficiency. Ther Drug Monit 1995 Oct; 17(5): 449–53.

    Article  PubMed  CAS  Google Scholar 

  11. Kremer JMH, Wilting J, Janssen LHM. Drug binding of human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988 March; 40(1): 1–47.

    PubMed  CAS  Google Scholar 

  12. Caswell M, Pike LA, Bull BS, et al. Effect of patient age on tests of acute-phase response. Arch Pathol Lab Med 1993 Sep; 117(9): 906–10.

    PubMed  CAS  Google Scholar 

  13. Crook MA, Treloar A, Haq M, et al. Serum total sialic acid and other acute phase proteins in elderly subjects. Eur J Clin Chem Clin Biochem 1994 Oct; 32(10): 745–7.

    PubMed  CAS  Google Scholar 

  14. Lalonde RL, Tenero DM, Burlew BS, et al. Effects of age on the protein binding and disposition of propranolol stereoisomers. Clin Pharmacol Ther 1990 Apr; 47(4): 447–55.

    Article  PubMed  CAS  Google Scholar 

  15. Veering BT, Burm AG, Souverijn JH, et al. The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein. Br J Clin Pharmacol 1990 Feb; 29(2): 201–6.

    Article  PubMed  CAS  Google Scholar 

  16. Ecoffey C. Pharmacokinetics of local anesthetics in children. Cah Anesthesiol 1992; 40(7): 533–6.

    PubMed  CAS  Google Scholar 

  17. Seta N, Tissot B, Forestier F, et al. Changes in alpha 1-acid glycoprotein serum concentrations and glycoforms in the developing human fetus. Clin Chim Acta 1991 Dec; 203(2–3): 167–75.

    Article  PubMed  CAS  Google Scholar 

  18. Bardy AH, Hiilesmaa VK, Teramo K, et al. Protein binding of antiepileptic drugs during pregnancy, labor and puerperium. Ther Drug Monit 1990 Jan; 12(1): 40–6.

    Article  PubMed  CAS  Google Scholar 

  19. Notarianni LJ. Plasma protein binding of drugs in pregnancy and in neonates. Clin Pharmacokinet 1990 Jan; 18(1): 20–36.

    Article  PubMed  CAS  Google Scholar 

  20. Maher JE, Goldenberg RL, Tamura T, et al. Albumin levels in pregnancy: a hypothesis — decreased levels of albumin are related to increased levels of alpha-fetoprotein. Early Hum Dev 1993 Oct; 34(3): 209–15.

    Article  PubMed  CAS  Google Scholar 

  21. Meistelman C, Benhamou D, Barre J, et al. Effects of age on plasma protein binding of sufentanil. Anesthesiology 1990 Mar; 72(3): 470–3.

    Article  PubMed  CAS  Google Scholar 

  22. Jensen H, Rossing N, Andersen SB, et al. Albumin metabolism in the nephrotic syndrome in adults. Clin Sci 1967 Dec; 33(3): 445–57.

    PubMed  CAS  Google Scholar 

  23. Vasson MP, Baguet JC, Arveiller MR, et al. Serum and urinary alpha-1 acid glycoprotein in chronic renal failure. Nephron 1993; 65(2): 299–303.

    Article  PubMed  CAS  Google Scholar 

  24. Movin-Osswald G, Boelaert J, Hammarlund-Udenaes M, et al. The pharmacokinetics of remoxipride and metabolites in patients with various degrees of renal function. Br J Clin Pharmacol 1993 Jun; 35(6): 615–22.

    Article  PubMed  CAS  Google Scholar 

  25. Vasson MP, Paul JL, Couderc R, et al. Serum alpha-1 acid glycoprotein in chronic renal failure and hemodialysis. Int J Artif Organs 1991 Feb; 14(2): 92–6.

    PubMed  CAS  Google Scholar 

  26. Pacifici GM, Viani A, Taddeuci-Brunelli G, et al. Effects of development, aging, and renal and hepatic insufficiency as well as hemodialysis on the plasma concentrations of albumin and α1-acid glycoprotein: implications for binding of drugs. Ther Drug Monit 1986; 8(3): 259–63.

    Article  PubMed  CAS  Google Scholar 

  27. Garcia-Morillas M, Gil-Extremera B, Caracuel-Ruiz. Differential effects of hepatic cirrhosis on the plasma protein binding of drugs. Int J Clin Pharmacol Res 1984; 4(5): 327–33.

    PubMed  CAS  Google Scholar 

  28. Hallen J, Laurell CB. Plasma protein pattern in cirrhosis of the liver. Scand J Clin Lab Invest Suppl 1972; 124: 97–103.

    CAS  Google Scholar 

  29. Kindmark CO, Laurell CB. Sequential changes of the plasma protein pattern in inoculation hepatitis. Scand J Clin Lab Invest Suppl 1972; 124: 105–15.

    Article  PubMed  CAS  Google Scholar 

  30. Joelsson B, Alwmark A, Gullstrand P, et al. Serum proteins in liver cirrhosis: effects of shunt surgery. J Clin Chem Clin Biochem 1987 Dec; 25(12): 865–8.

    PubMed  CAS  Google Scholar 

  31. Biou D, Chanton P, Konan D, et al. Microheterogeneity of the carbohydrate moiety of human α1-acid glycoprotein in two benign liver diseases: alcoholic cirrhosis and acute hepatitis. Clin Chim Acta Dec 1989; 186(1): 59–66.

    Article  CAS  Google Scholar 

  32. Falleti E, Pirisi M, Fabris C, et al. Increase of serum alpha 1-acid glycoprotein despite the decline of liver synthetic function in cirrhotics with hepatocellular carcinoma. Eur J Clin Chem Clin Biochem 1993 Jul; 31(7): 407–11.

    PubMed  CAS  Google Scholar 

  33. Viani A, Rizzo G, Carrai M, et al. Interindividual variability in the concentrations of albumin and alpha-1-acid glycoprotein in patients with renal or liver disease, newborns and healthy subjects: implications for binding of drugs. Int J Clin Pharmacol Ther Toxicol 1992 Apr; 30(4): 128–33.

    PubMed  CAS  Google Scholar 

  34. Piafsky KM, Borgä O, Odar-Cederlöf I, et al. Increased plasma protein binding of propranolol and chloropromazine mediated by disease induced elevations of plasma α1-acid glycoprotein. N Engl J Med 1978 Dec; 299(26): 1435–9.

    Article  PubMed  CAS  Google Scholar 

  35. Bloedow DC, Hansrough JF, Hardin T, et al. Postburn serum drug binding and serum concentrations. J Clin Pharmacol 1986 Feb; 26(2): 147–51.

    PubMed  CAS  Google Scholar 

  36. Martyn JAJ, Abernethy DR, Greenblatt DJ. Plasma protein binding of drugs after severe burn injury. Clin Pharmacol Ther 1984 Apr; 35(4): 535–9.

    Article  PubMed  CAS  Google Scholar 

  37. Tozer TN. Implication of altered plasma protein binding in disease states. In: Benet LZ, Massourd N, Garbetoglio JG, et al., editors. Pharmacokinetic basis for drug treatment. New York: Raven Press, 1984.

    Google Scholar 

  38. Hooper WD, Bochner F, Eadie MJ, et al. Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal, and hepatic disease. Clin Pharmacol Ther 1974 Mar; 15: 276–82.

    PubMed  CAS  Google Scholar 

  39. Wallace S, Brodie MJ. Decreased drug binding in serum from patients with chronic hepatic disease. Eur J Clin Pharmacol 1976 Mar; 9(5–6): 429–32.

    Article  CAS  Google Scholar 

  40. Riuz-Cabello F, Erill S. Abnormal serum protein binding of acidic drugs in diabetes mellitus. Clin Pharmacol Ther 1984; 36: 691–5.

    Article  Google Scholar 

  41. Grossman SH, Davis D, Kitchell BB, et al. Diazepam and lidocaine plasma protein binding in renal disease. Clin Pharmacol Ther 1982 Mar; 31(3): 350–7.

    Article  PubMed  CAS  Google Scholar 

  42. Thiessen JJ, Sellers EM, Denbeigh P, et al. Plasma protein binding of diazepam and tolbutamide in chronic alcoholics. J Clin Pharmacol 1976 Jul; 16(7): 345–51.

    PubMed  CAS  Google Scholar 

  43. Feely J, Stevenson IH, Crooks J. Altered plasma protein binding of drugs in thyroid disease. Clin Pharmacokinet 1981 Jul-Aug; 6(4): 298–305.

    Article  PubMed  CAS  Google Scholar 

  44. Kurz H, Trunk H, Wetrz B. Evaluation of methods to determine protein binding of drugs. Arzneimittel Forschung 1977 Jul; 27(7): 1373–80.

    PubMed  CAS  Google Scholar 

  45. Chigell CU. Protein binding. In: Garnett Er, Hirtz JL, editors. Drug fate and metabolism. Vol 1. New York: Marcel Dekker, 1977: 187–228.

    Google Scholar 

  46. Bowers WF, Fulton S, Thompson J. Ultrafiltration vs. equilibrium dialysis for determination of free fraction. Clin Pharmacokinet 1984 Jan; 9 Suppl. 1: 49–60.

    Article  Google Scholar 

  47. Pacifici GM, Viana A. Methods of determining plasma and tissue binding of drugs: pharmacokinetic consequences. Clin Pharmacokinet 1992 Dec; 23(6): 449–68.

    Article  PubMed  CAS  Google Scholar 

  48. Muller M, Scmid R, Georgopoulos A, et al. Application of microdialysis to clinical pharmacokinetics in humans. Clin Pharmacol Ther 1995 Apr; 57(4): 371–80.

    Article  PubMed  CAS  Google Scholar 

  49. Schentag JJ, Ballow CH. Tissue directed pharmacokinetics. Am J Med 1991 Sep 12; 91(3A): 5–11.

    Article  Google Scholar 

  50. Craig WA, Welling PG. Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet 1977 Jul-Aug; 2(4): 252–68.

    Article  PubMed  CAS  Google Scholar 

  51. Vallner JJ. Binding of drugs by albumin and plasma protein. J Pharm Sci 1977 Apr; 66(4): 447–63.

    Article  PubMed  CAS  Google Scholar 

  52. Jusko WJ, Gretch M. Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metab Rev 1976; 5(1): 43–140.

    Article  CAS  Google Scholar 

  53. Sanderberg AA, Slaunwhite WR, Antoniades HN. The binding of steroids and steroid conjugates to human plasma proteins. Recent Progr Horm Res 1957; 13: 209–67.

    Google Scholar 

  54. Ballard PL. Delivery and transport of glucocorticoids to target cells. Monogr Endocrinol 1979; 12: 25–48.

    Article  PubMed  CAS  Google Scholar 

  55. Lemaire M, Urien S, Albengres((intials?)), et al. Lipoprotein binding of drugs. In: Reidenberg MM, Erill S, editors. Drugprotein binding. New York: Praeger Publishers, 1986: 36–45.

    Google Scholar 

  56. MacKichan J. Influence of protein binding and use of unbound (free) drug concentrations (chapter 5). In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. Spokene (WA): Applied Therapeutics, Inc, 1993: 1–48.

    Google Scholar 

  57. Pike E, Skuterud B, Kierulf P, et al. The relative importance of albumin, lipoproteins and orosomucoid for drug serum binding. Clin Pharmacokinet 1984; 9 Suppl. 1: 84–101.

    Article  CAS  Google Scholar 

  58. Kragh-Hansen U. Molecular aspects of ligand binding to serum albumin. Pharmacol Rev 1981 Mar; 33(1): 17–53.

    PubMed  CAS  Google Scholar 

  59. Klotz IM, Physicochemical aspects of drug-protein interactions: a general perspective. Ann N Y Acad Sci 1973 Nov 26; 226: 18–35.

    Article  PubMed  CAS  Google Scholar 

  60. Peters T. Serum albumin. In: Putnam FW, editor. The plasma proteins: structure, function and genetic control. New York: Academic Press, 1975: 133–87.

    Google Scholar 

  61. Iwatsuru M, Nishigori H, Maruyama K. The classification of drugs on the basis of the drug-binding site on human serum albumin. Chem Pharm Bull 1982 Dec; 30(2): 4489–93.

    Article  PubMed  CAS  Google Scholar 

  62. Sudlow G, Birkett DJ, Wade DN. The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol 1975 Nov; 11(6): 824–32.

    PubMed  CAS  Google Scholar 

  63. Schmid K. α-1-acid glycoprotein. In: Putnam FW, editor. The plasma proteins: structure, function and genetic control. New York: Academic Press, 1975: 183–228.

    Google Scholar 

  64. Scanu AM, Edelstein C, Keim P. Serum lipoproteins. In: Putnam FW, editor. The plasma proteins: structure, function and genetic control. New York: Academic Press, 1975: 317–91.

    Google Scholar 

  65. Pucino F, Beck CL, Seifert RL, et al. Pharmacogeriatics. Pharmacotherapy 1985 Nov-Dec; 5(6): 314–26.

    PubMed  CAS  Google Scholar 

  66. Cohen JL. Pharmacokinetic changes in aging. Am J Med 1986 May 16; 80(5A Suppl.): 31–8.

    Article  PubMed  CAS  Google Scholar 

  67. Dawling S, Crome P. Clinical pharmacokinetic considerations in the elderly: an update. Clin Pharmacokinet 1989 Oct; 17(4): 236–63.

    Article  PubMed  CAS  Google Scholar 

  68. Greenblatt DJ. Reduced serum albumin concentration in the elderly: a report from the Boston Collaborative Drug Surveillance Program. J Am Geriatr Soc 1979 Jan; 27(1): 20–2.

    PubMed  CAS  Google Scholar 

  69. Leslie C, Scott PJW, Caird FI. Principles of alterations to drug kinetics and dynamics in the elderly. Med Lab Sci 1992 Dec; 49(4): 319–25.

    PubMed  CAS  Google Scholar 

  70. Rowland M. Protein binding and drug clearance. Clin Pharmacokinet 1984 Jan; 9 Suppl. 1: 10–7.

    Article  PubMed  CAS  Google Scholar 

  71. Smallwood RH, Mihaly GW, Smallwood RA, et al. Effect of a protein change on unbound and total plasma concentrations for drugs of intermediate hepatic extraction. J Pharmacokinet Biopharm 1988 Oct; 16(5): 529–42.

    PubMed  CAS  Google Scholar 

  72. Huang J, Øie S. Hepatic elimination of drugs with concentration-dependent serum protein binding. J Pharmacokinet Biopharm 1984 Feb; 12(1): 67–81.

    PubMed  CAS  Google Scholar 

  73. Faed EM. Protein binding of drugs in plasma, interstital fluid and tissues: effect on pharmacokinetics. Eur J Clin Pharmacol 1981; 21(1): 77–81.

    Article  PubMed  CAS  Google Scholar 

  74. McNamara PJ, Levy G, Gibaldi M. Effect of plasma protein and tissue binding on the time course of drug concentration in plasma. J Pharmacokinet Biopharm 1979; 7(2): 195–206.

    PubMed  CAS  Google Scholar 

  75. Wilkinson GR. Plasma and tissue binding considerations in drug disposition. Drug Metab Rev 1983; 14(3): 427–65.

    Article  PubMed  CAS  Google Scholar 

  76. Wallace SM, Verbeeck RK. Plasma protein binding of drugs in the elderly. Clinical pharmacokinetics in the elderly. Clin Pharmacokinet 1987 Jan; 12(1): 41–7.

    Article  PubMed  CAS  Google Scholar 

  77. Wagner JG, Northam JI, Alway CD, et al. Blood levels at the equilibrium state after multiple dosing. Nature 1965 Sep 18; 207(3): 1301–2.

    Article  PubMed  CAS  Google Scholar 

  78. Kutt H, Winters W, Kokenga R, et al. Diphenylhydantoin metabolism, blood levels and toxicity. Arch Neurol 1964; 11: 642–8.

    Article  PubMed  CAS  Google Scholar 

  79. Piquette-Miller M, Foster RT, Kappagoda CT, et al. Effect of aging on the pharmacokinetics of acebutolol enantiomers. J Clin Pharmacol 1992 Feb; 32(2): 148–56.

    PubMed  CAS  Google Scholar 

  80. Chapron DJ, Sweeney KR, Feig PU, et al. Influence of advanced age on the disposition of acetazolamide. Br J Clin Pharmacol 1985 Mar; 19(3): 363–71.

    Article  PubMed  CAS  Google Scholar 

  81. Gomolin IH, Chapron DJ. Elucidating the relationship between acetazolamide plasma protein binding and renal clearance using an albumin infusion. J Clin Pharmacol 1992 Nov; 32(11): 1028–32.

    PubMed  CAS  Google Scholar 

  82. Lemmens HJM, Burn AGL, Bouill JG, et al. Pharmacodynamics of alfentanil: the role of plasma protein binding. Anesthesiology 1992 Jan; 76(1): 65–70.

    Article  PubMed  CAS  Google Scholar 

  83. Belpaire FM, Bogaert MG. Binding of alfentanil to human αi- acid glycoprotein, albumin and serum. Int J Clin Pharmacol Ther Tox 1991 Mar; 29(3): 96–102.

    CAS  Google Scholar 

  84. Greenblatt DJ, Divoll M, Abernethy DR, et al. Alprazolam kinetics in the elderly: relation to antipyrine disposition. Arch Gen Psychiatry 1983 Mar; 40(3): 287–90.

    Article  PubMed  CAS  Google Scholar 

  85. Schulz P, Turner-Tamiyasu K, Smith G, et al. Amitriptyline disposition in young and elderly normal men. Clin Pharmacol Ther 1983 Mar; 33(3): 360–6.

    Article  PubMed  CAS  Google Scholar 

  86. St Peter JV, Brady ME, Foote EF, et al. The disposition and protein binding of batanopride and its metabolites in subjects with renal impairment. Eur J Clin Pharmacol 1993; 45(1): 59–63.

    Article  PubMed  CAS  Google Scholar 

  87. Kaiser G, Ackermann R, Durnin CJ, et al. Pharmacokinetics and pharmacodynamics of the ACE inhibitor benazepril hydrochloride in the elderly. Eur J Clin Pharmacol 1990; 38(4): 379–85.

    Article  PubMed  CAS  Google Scholar 

  88. MacDonald NJ, Sioufi A, Howie CA, et al. The effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril. Br J Clin Pharmacol 1993 Sep; 36(3): 205–9.

    Article  PubMed  CAS  Google Scholar 

  89. Ho PC, Bourne DWA, Triggs EJ, et al. Comparison of plasma levels of canrenone and metabolites after base hydrolysis in young and elderly subjects following single and multiple doses of spironolactone. Eur J Clin Pharmacol 1984; 27: 435–9.

    Article  PubMed  CAS  Google Scholar 

  90. Blanchard J. Protein binding of caffeine in young and elderly males. J Pharm Sci 1982 Dec; 71(12): 1415–8.

    Article  PubMed  CAS  Google Scholar 

  91. Karki SD, Bentley DW, Luzier A, et al. Disposition of intramuscular cefonicid in elderly patients. J Am Geriatr Soc 1993 Aug; 41(8): 808–10.

    PubMed  CAS  Google Scholar 

  92. Dudley MN, Shyu WC, Nightingale CH. Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans. Antimicrob Agents Chemother 1986 Oct; 30(4): 565–9.

    Article  PubMed  CAS  Google Scholar 

  93. Luderer JR, Patel IH, Durkin J, et al. Age and ceftriaxone kinetics. Clin Pharmacol Ther 1984 Jan; 35(1): 19–25.

    Article  PubMed  CAS  Google Scholar 

  94. Roberts RK, Wilkerson GR, Branch RA, et al. Effect of age and parenchymal liver disease on the disposition and elimination of chlorodiazepoxide. Gastroenterology 1978 Sep; 75(3): 479–85.

    PubMed  CAS  Google Scholar 

  95. Verbeeck RK, Cardinal JA, Wallace SM. Effect of age and sex on the plasma binding of acidic and basic drugs. Eur J Clin Pharmacol 1984; 27(1): 91–7.

    PubMed  CAS  Google Scholar 

  96. Walker O, Birkett DJ, Alvan G, etal. Characterization of chloroquine plasma protein binding in man. Br J Clin Pharmacol 1983 Mar; 15(3): 375–7.

    Article  PubMed  CAS  Google Scholar 

  97. Augustijns P, Verbeerke N. Stereoselective pharmacokinetic properties of chloroquine and de-ethyl chloroquine in humans. Clin Pharmacokinet 1993 Mar; 24(3): 259–69.

    Article  PubMed  CAS  Google Scholar 

  98. Albertioni F, Heronren L. Protein binding of 2-chloro-2′-deoxyadenosine (cladribine) in healthy subjects and in patients with leukaemia. Eur J Clin Pharmacol 1994; 46(6): 563–4.

    Article  PubMed  CAS  Google Scholar 

  99. Nation RL, Vine J, Triggs EJ, et al. Plasma levels of chlormethiazole and two metabolites after oral administration to young and aged subjects. Eur J Clin Pharmacol 1977 Oct 14; 12(2): 137–45.

    Article  PubMed  CAS  Google Scholar 

  100. Abernathy DR, Greenblatt DJ, Shader RL Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther 1985 Jan; 232(1): 183–8.

    Google Scholar 

  101. Allen MD, Greenblatt DJ. Comparative protein binding of diazepam and desmethydiazepam. J Clin Pharmacol 1981 May-Jun; 21(5–6): 219–23.

    PubMed  CAS  Google Scholar 

  102. Shader RI, Greenblatt DJ, Cirraulo DA, et al. Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate. Psychopharmacology 1981; 75(2): 193–7.

    Article  PubMed  CAS  Google Scholar 

  103. Viani A, Rizzo G, Carrai M, et al. The effect of aging on plasma albumin and plasma protein binding of diazepam, salicyclic acid, and digitoxin in healthy subjects and patients with renal impairment. Br J Clin Pharmacol 1992 Mar; 33(3): 299–304.

    Article  PubMed  CAS  Google Scholar 

  104. Greenblatt DJ, Allen MD, Harmatz JS, et al. Diazepam disposition determinants. Clin Pharmacol Ther 1980; 27: 302–12.

    Article  Google Scholar 

  105. Verbeeck RK, De Schepper PJ. Influence of chronic renal failure and hemodialysis on diflunisal plasma protein binding. Clin Pharmacol Ther 1980; 27: 628–35.

    Article  PubMed  CAS  Google Scholar 

  106. Bonde J, Pedersen LE, Bødfker S, et al. The influence of age and smoking on the elimination of disopyramide. Br J Clin Pharmacol 1985 Nov; 20(5): 453–8.

    Article  PubMed  CAS  Google Scholar 

  107. Ohnishi A, Mihara M, Kamakura H, et al. Comparsion of the pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy young and elderly subjects. J Clin Pharmacol 1993 Nov; 33(11): 1086–91.

    PubMed  CAS  Google Scholar 

  108. Scatina J, Hicks D, Kraml M, et al. Etodalac kinetics in the elderly. Clin Pharmacol Ther 1986 May; 39(5): 550–3.

    Article  PubMed  CAS  Google Scholar 

  109. Carlos R, Calvo R, Erill S. Plasma protein binding of etomidate in different age groups and in patients with chronic respiratory insufficiency. Int J Clin Pharmacol Ther Toxicol 1981 Apr; 19(4): 171–4.

    PubMed  CAS  Google Scholar 

  110. Greenblatt DJ, Divoll M, Harmatz JS, et al. Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin Pharmacol Ther 1981 Oct; 30(4): 475–86.

    Article  PubMed  CAS  Google Scholar 

  111. Andreasen F, Hansen U, Husted SE, et al. The pharmacokinetics of frusemide are influenced by age. Br J Clin Pharmacol 1983 Oct; 16(4): 391–7.

    Article  PubMed  CAS  Google Scholar 

  112. Rowell FJ, Hui SM, Fairburn AF, et al. Total and free serum haloperidol levels in schizophrenic patients and the effect of age, thioridazine and fatty acids on haloperidol serum protein binding in vitro. Br J Clin Pharmacol 1981 Apr; 11(4): 377–82.

    Article  PubMed  CAS  Google Scholar 

  113. Rudy AC, Knight PM, Brater DC, et al. Enantioselective disposition of ibuprofen on elderly persons with and without renal impairment. J Pharmacol Exp Ther 1995 Apr; 273(1): 88–93.

    PubMed  CAS  Google Scholar 

  114. Cusack B, O’Malley K, Lavan J, et al. Protein binding and disposition of lignocaine in the elderly. Eur J Clin Pharmacol 1985; 29(3): 323–9.

    Article  PubMed  CAS  Google Scholar 

  115. Divoll M, Greenblatt DJ. Effect of age and sex on lorazepam protein binding. J Pharm Pharmacol 1982 Feb; 34(2): 122–3.

    Article  PubMed  CAS  Google Scholar 

  116. Norbury HM, Franklin RA, Graham DF. Pharmacokinetics of the new analgesic, meptazinol after oral and intravenous administration to volunteers. Eur J Clin Pharmacol 1983; 25(1): 77–80.

    Article  PubMed  CAS  Google Scholar 

  117. Norbury HM, Franklin RA, Graham DF, et al. Pharmacokinetics of meptazinol after single and multiple oral administration to elderly patients. Eur J Clin Pharmacol 1984; 27: 223–6.

    Article  PubMed  CAS  Google Scholar 

  118. Edno L, Bressolle F, Gomeni R, et al. Total and free methotrexate pharmacokinetics in rheumatoid arthritis patients. Ther Drug Monit 1996; 18: 128–34.

    Article  PubMed  CAS  Google Scholar 

  119. Rigby JW, Scott AK, Hawksworth GM, et al. A comparsion of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young subjects. Br J Clin Pharmacol 1985 Oct; 20(4): 327–31.

    Article  PubMed  CAS  Google Scholar 

  120. Greenblatt DJ, Abernathy DR, Locniskar A, et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984 Jul; 61(1): 27–45.

    PubMed  CAS  Google Scholar 

  121. Cook CS, Schoenhard GL, Karim A. Effect of salicylic acid on the plasma protein binding and the misoprostol acid. J Pharm Sci 1994 Jun; 83(6): 883–6.

    Article  PubMed  CAS  Google Scholar 

  122. Upton RA, Williams RL, Kelly J, et al. Naproxen pharmacokinetics in the elderly. Br J Clin Pharmacol 1984; 18: 207–14.

    Article  PubMed  CAS  Google Scholar 

  123. Sugioka N, Koyama H, Kawakubo M, et al. Age-dependent alteration of the serum-unbound fraction of nicardipine, a calcium-channel blocker, in man. J Pharm Pharmacol 1996 Dec; 48(12): 1327–31.

    Article  PubMed  CAS  Google Scholar 

  124. Jochemsen R, Van Beusekom Br, Spoelstra P, et al. Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam. Br J Clin Pharmacol 1983 Mar; 15(3): 295–302.

    Article  PubMed  CAS  Google Scholar 

  125. Greenblatt DJ, Abernathy DR, Locniskar A, et al. Age, sex and nitrazepam kinetics: relation to antipyrine disposition. Clin Pharmacol Ther 1985 Dec; 38(6): 697–703.

    Article  PubMed  CAS  Google Scholar 

  126. Greenblatt DJ, Matlis R, Scavone JM, et al. Oxaprozin kinetics in the elderly. Br J Clin Pharmacol 1985 Jan; 19(1): 373–8.

    Article  PubMed  CAS  Google Scholar 

  127. Karim A, Noveck R, McMahon G, et al. Oxaprozin and piroxicam, nonsteriodal anti-inflammatory drugs with long half-lives: effect of protein binding differences on steady state pharmacokinetics. J Clin Pharmacol 1997 Apr; 37(4): 267–78.

    PubMed  CAS  Google Scholar 

  128. Mather LE, Tucker GT, Pflug AE, et al. Meperidine kinetics in man: intravenous injection in surgical patients and volunteers Clin Pharmacol Ther 1975 Jan; 17(1): 21–30.

    PubMed  CAS  Google Scholar 

  129. Holmberg L, Odar-Cederlöft I, Nilsson JLG, et al. Pethidine binding to blood cells and plasma proteins in old and young subjects. Eur J Clin Pharmacol 1982; 22(2): 457–61.

    Article  Google Scholar 

  130. Bender AD, Post A, Meier JP, et al. Plasma protein binding of drugs as a function of age. J Pharm Sci 1975 Oct; 64(10): 1711–3.

    Article  PubMed  CAS  Google Scholar 

  131. Patterson M, Heazelwood R, Smithhurst B, et al. Plasma protein binding of phenytoin in the aged: in vivo studies. Br J Clin Pharmacol 1982 Mar; 13(3): 423–5.

    Article  PubMed  CAS  Google Scholar 

  132. Richardson CJ, Blocka KLN, Ross SG, et al. Effect of age and sex on piroxicam disposition. Clin Pharmacol Ther 1985 Jan; 37(1): 13–8.

    Article  PubMed  CAS  Google Scholar 

  133. Trovik TS, Jaeger R, Jorde R, et al. Plasma protein binding of catecholamines, prazosin and propranolol in diabetes mellitus. Eur J Clin Pharmacol 1992; 43(3): 265–8.

    Article  PubMed  CAS  Google Scholar 

  134. Andros E, Detmar-Hanna D, Suteparuk S, et al. The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin. Eur J Clin Pharmacol 1996; 50: 41–6.

    Article  PubMed  CAS  Google Scholar 

  135. Tenero DM, Bottorff MB, Burlew BS. Altered beta-adrenergic sensitivity and protein binding to l-propranolol in the elderly. J Cardiovasc Pharmacol 1990 Nov; 16(5) 702–7.

    Article  PubMed  CAS  Google Scholar 

  136. Gilmore DA, Gal J, Gerber JG, et al. Age and gender influence the stereoselective pharmacokinetics of propranolol. J Pharmacol Exp Ther 1992 Jun; 261(3): 1181–6.

    PubMed  CAS  Google Scholar 

  137. Bendayan R, Pieper JA, Stewart RB, et al. Influence of age on serum protein binding of propranolol. Eur J Clin Pharmacol 1984; 26(2): 251–4.

    Article  PubMed  CAS  Google Scholar 

  138. Colagelo P, Chandler M, Bloiun R, et al. Stereoselective binding of propranolol in the elderly. Br J Clin Pharmacol 1989; 27: 519–22.

    Article  Google Scholar 

  139. Barber HE, Hawksworth GM, Petrie JC, et al. Pharmacokinetics of atenolol and propranolol in young and elderly subjects [abstract]. Br J Clin Pharmacol 1981; 11: 118P–9P.

    CAS  Google Scholar 

  140. Ochs HR, Greenblatt DJ, Woo E, et al. Reduced quinidine clearance in elderly persons. Am J Cardiol 1978 Sep; 42(3): 481–5.

    Article  PubMed  CAS  Google Scholar 

  141. Snoeck E, Van Peer A, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 1995; 122: 223–9.

    Article  PubMed  CAS  Google Scholar 

  142. Roberts MS, Rumble RH, Wanwimolruk S, et al. Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease. Eur J Clin Pharmacol 1983; 25(2): 253–61.

    Article  PubMed  CAS  Google Scholar 

  143. Lesko LJ, Narang PK, Yeager L, et al. Salicylate protein binding in serum from young and elderly subjects as measured by diafiltration. Eur J Clin Pharmacol 1985; 28(3): 339–45.

    Article  PubMed  CAS  Google Scholar 

  144. Carr RA, Pasutto FM, Lewanczuk RZ, et al. Protein binding of sotalol enantiomers in young and elderly human and rat serum using ultrafiltration. Biopharm Drug Dispos 1995 Nov; 16(8): 705–12.

    Article  PubMed  CAS  Google Scholar 

  145. Varoquaux O, LaJoie D, Gobart C, et al. Pharmacokinetics of the trimethoprim-sulphamethoxazole combination in the elderly. Br J Clin Pharmacol 1985 Dec; 20(6): 575–81.

    Article  PubMed  CAS  Google Scholar 

  146. Caldwell JR, Kirby DS, Gardner MJ, et al. The effects of age and gender on the pharmacokinetics of tenidap sodium in patients with rheumatoid arthritis and osteoarthritis. Br J Clin Pharmacol 1995; 39(1 Suppl.): 3S–9S.

    Article  PubMed  Google Scholar 

  147. Shin SG, Juan D, Rammohan M. Theophylline pharmacokinetics in normal elderly subjects. Clin Pharmacol Ther 1988 Nov; 44(5): 522–30.

    Article  PubMed  CAS  Google Scholar 

  148. Antal EJ, Kramer PA, Mercik SA, et al. Theophylline pharmacokinetics in advanced age. Br J Clin Pharmcol 1981; 12(5) 637–45.

    Article  CAS  Google Scholar 

  149. Lesko LJ, Tabor KJ, Johnson BE Theophylline serum protein binding in obstructive airways disease. Clin Pharmacol Ther 1981 Jun; 29(6): 776–81.

    Article  PubMed  CAS  Google Scholar 

  150. Nilsen OG, Storhaug A, Dale O. Binding of tiaprofenic acid to human sera and isolated serum proteins. Arzneimettel Forschung 1985; 35(6); 984–7.

    CAS  Google Scholar 

  151. Greenblatt DJ, Divoll M, Abernathy DR, et al. Reduced clearance of triazolam in old age: relationot antipyrine oxidizing capacity. Br J Clin Pharmacol 1983 Mar; 15(3): 303–9.

    Article  PubMed  CAS  Google Scholar 

  152. Perucca E, Grimaldi R, Gotti G, et al. Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol 1984 Jun; 17(6): 665–9.

    Article  PubMed  CAS  Google Scholar 

  153. Bauer LA, Davis R, Wilensky A, et al. Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults. Clin Pharmacol Ther 1985 Jun; 37(6): 697–700.

    Article  PubMed  CAS  Google Scholar 

  154. Cutler NR, Narang PK, Lesko LJ, et al. Vancomycin disposition: the importance of age. Clin Pharmacol Ther 1984; 36: 803–9.

    Article  PubMed  CAS  Google Scholar 

  155. Wood DM, Ford JM, Roberts CJC. Variability in the plasma protein binding of velnacrine: a potential agent for Alzheimer’s disease. Eur J Clin Pharmacol 1996; 50: 115–9.

    Article  PubMed  CAS  Google Scholar 

  156. Schwartz JB, Capili H, Daugherty J. Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1994; 509–17.

    Google Scholar 

  157. Shepherd AMM, Hewick DS, Moreland TA, et al. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol 1977 Jun; 4(3): 315–20.

    Article  PubMed  CAS  Google Scholar 

  158. Braeckman RA, Granneman GR, Locke CS, et al. The pharmacokinetics of zileuton in healthy young and elderly volunteers. Clin Pharmacokinet 1995; 29: 42–8.

    Article  PubMed  CAS  Google Scholar 

  159. Van Den Ouweland FA, Jansen PAF, Tan Y, et al. Pharmacokinetics of high-dosage naproxen in elderly patients. Int J Clin Pharmacol Ther Toxicol 1988; 26(3): 143–7.

    PubMed  Google Scholar 

  160. Hundal Ø, Rugstad HE, Husby G. Naproxen free plasma concentrations and unbound fractions in patients with osteoarthritis: relation to age, sex, efficacy and adverse events. Ther Drug Monit 1991; 13: 478–84.

    Article  PubMed  CAS  Google Scholar 

  161. Satterwhite JH, Boudinot FD. Age- and dose-dependent naproxen disposition in Fischer 334 rats. J Gerontol 1991; 46(6): B222–7.

    Article  PubMed  CAS  Google Scholar 

  162. Satterwhite JH, Boudinot FD. Effects of age on the pharmacodynamics of naproxen in the rat. Exp Gerontol 1995; 30(5): 505–15.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, Georgia, 30602-2352, USA

    Monica K. Grandison &  F. Douglas Boudinot

Authors
  1. Monica K. Grandison
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Douglas Boudinot
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Douglas Boudinot.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grandison, M.K., Boudinot, F.D. Age-Related Changes in Protein Binding of Drugs. Clin Pharmacokinet 38, 271–290 (2000). https://doi.org/10.2165/00003088-200038030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200038030-00005

Keywords

Search

Navigation